| Dr Michael Daneshvar, MD, MS | |
|
101 The City Dr S, Orange, CA 92868-3201 | |
| (714) 880-7812 | |
| Not Available |
| Full Name | Dr Michael Daneshvar |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 9 Years |
| Location | 101 The City Dr S, Orange, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194103861 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | D0089555 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of California Irvine Medical Center | Orange, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Uci Department Of Urology | 6901799238 | 26 |
News Archive
XTL Biopharmaceuticals Ltd., a biopharmaceutical development company, announced on November 21st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium).
Two new studies in the February 16 issue of the Journal of the National Cancer Institute examine the effects of coffee consumption on the incidence of liver and colorectal cancers. One study found that drinking coffee daily is associated with a decreased risk of liver cancer, while the other found no association between drinking coffee or tea and the risk of colorectal cancer.
Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, announced today that the paper entitled, "Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects," authored by Dr. Roy Eldor, Dr. Miriam Kidron and Dr. Ehud Arbit, was accepted and published in the Diabetes, Obesity and Metabolism journal.
A receptor that plays an essential role in safely clearing chronic unresolved cardiac inflammation may offer new targets for treating an increasing type of heart failure associated with age-related obesity, suggests a preclinical study led by researchers at the University of South Florida Health Heart Institute, Morsani College of Medicine.
ntegral Molecular, Inc., a leader in membrane protein reagents and services, announces the launch of its Membrane Protein Solutions antibody discovery platform.
› Verified 4 days ago
| Entity Name | Uci Department Of Urology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255398533 PECOS PAC ID: 6901799238 Enrollment ID: O20040202001148 |
News Archive
XTL Biopharmaceuticals Ltd., a biopharmaceutical development company, announced on November 21st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium).
Two new studies in the February 16 issue of the Journal of the National Cancer Institute examine the effects of coffee consumption on the incidence of liver and colorectal cancers. One study found that drinking coffee daily is associated with a decreased risk of liver cancer, while the other found no association between drinking coffee or tea and the risk of colorectal cancer.
Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, announced today that the paper entitled, "Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects," authored by Dr. Roy Eldor, Dr. Miriam Kidron and Dr. Ehud Arbit, was accepted and published in the Diabetes, Obesity and Metabolism journal.
A receptor that plays an essential role in safely clearing chronic unresolved cardiac inflammation may offer new targets for treating an increasing type of heart failure associated with age-related obesity, suggests a preclinical study led by researchers at the University of South Florida Health Heart Institute, Morsani College of Medicine.
ntegral Molecular, Inc., a leader in membrane protein reagents and services, announces the launch of its Membrane Protein Solutions antibody discovery platform.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Daneshvar, MD, MS 200 S Manchester Ave Ste 300, Orange, CA 92868-3219 Ph: (714) 456-2986 | Dr Michael Daneshvar, MD, MS 101 The City Dr S, Orange, CA 92868-3201 Ph: (714) 880-7812 |
News Archive
XTL Biopharmaceuticals Ltd., a biopharmaceutical development company, announced on November 21st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium).
Two new studies in the February 16 issue of the Journal of the National Cancer Institute examine the effects of coffee consumption on the incidence of liver and colorectal cancers. One study found that drinking coffee daily is associated with a decreased risk of liver cancer, while the other found no association between drinking coffee or tea and the risk of colorectal cancer.
Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, announced today that the paper entitled, "Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects," authored by Dr. Roy Eldor, Dr. Miriam Kidron and Dr. Ehud Arbit, was accepted and published in the Diabetes, Obesity and Metabolism journal.
A receptor that plays an essential role in safely clearing chronic unresolved cardiac inflammation may offer new targets for treating an increasing type of heart failure associated with age-related obesity, suggests a preclinical study led by researchers at the University of South Florida Health Heart Institute, Morsani College of Medicine.
ntegral Molecular, Inc., a leader in membrane protein reagents and services, announces the launch of its Membrane Protein Solutions antibody discovery platform.
› Verified 4 days ago
Thomas E Ahlering, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-456-6068 Fax: 888-378-4524 | |
Dr. Jacob Basilius, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-880-7812 | |
Dr. Akhil K Das, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-880-7812 | |
Ahmed Abdelhalim Abdelaziz Ali, M.D. Urology Medicare: Medicare Enrolled Practice Location: 505 S Main St, Suite 100, Orange, CA 92868 Phone: 714-509-3914 | |
Dr. Hari Prashant Sawkar, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1140 W La Veta Ave Ste 520, Orange, CA 92868 Phone: 714-543-2000 Fax: 714-543-8804 | |
Dr. Zhan Tao Wang, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 505 S Main St Ste 100, Orange, CA 92868 Phone: 714-509-3914 Fax: 714-509-3915 | |
Heidi Ann Stephany, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 505 S Main St Ste 100, Orange, CA 92868 Phone: 714-509-3914 Fax: 888-378-5391 |